|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM188552235 |
| 003 |
DE-627 |
| 005 |
20231223182124.0 |
| 007 |
tu |
| 008 |
231223s2009 xx ||||| 00| ||eng c |
| 028 |
5 |
2 |
|a pubmed24n0629.xml
|
| 035 |
|
|
|a (DE-627)NLM188552235
|
| 035 |
|
|
|a (NLM)19444998
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 245 |
1 |
0 |
|a How do aspirin and nitroglycerin differ in heart attack prevention and treatment?
|
| 264 |
|
1 |
|c 2009
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ohne Hilfsmittel zu benutzen
|b n
|2 rdamedia
|
| 338 |
|
|
|a Band
|b nc
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 26.05.2009
|
| 500 |
|
|
|a Date Revised 21.10.2016
|
| 500 |
|
|
|a published: Print
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
7 |
|a Vasodilator Agents
|2 NLM
|
| 650 |
|
7 |
|a Nitroglycerin
|2 NLM
|
| 650 |
|
7 |
|a G59M7S0WS3
|2 NLM
|
| 650 |
|
7 |
|a Aspirin
|2 NLM
|
| 650 |
|
7 |
|a R16CO5Y76E
|2 NLM
|
| 773 |
0 |
8 |
|i Enthalten in
|t Heart advisor
|d 1999
|g 12(2009), 1 vom: 31. Jan., Seite 12
|w (DE-627)NLM098274252
|x 1523-9004
|7 nnns
|
| 773 |
1 |
8 |
|g volume:12
|g year:2009
|g number:1
|g day:31
|g month:01
|g pages:12
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 12
|j 2009
|e 1
|b 31
|c 01
|h 12
|